Neupogen Novum 0,96 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

neupogen novum 0,96 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

amgen europe bv - filgrastim - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,96 mg/ml

Accurate Delta Vanddispergerbart granulat Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

accurate delta vanddispergerbart granulat

fmc agricultural solutions a/s (tidligere: cheminova a/s) - diflufenican, metsulfuron-methyl, metsulfuron - vanddispergerbart granulat - 600 g/kg diflufenican ; 60 g/kg metsulfuron-methyl ; (~ 57,8 g/kg metsulfuron

Lodin 200 EC Flydende middel Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

lodin 200 ec flydende middel

agrichem b. v. - fluroxypyr - flydende middel - 200 g/l fluroxypyr

Stomp Suspensionskoncentrat Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

stomp suspensionskoncentrat

basf a/s - pendimethalin - suspensionskoncentrat - 400 g/l pendimethalin

Plenum 50 WG Vanddispergerbart granulat Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

plenum 50 wg vanddispergerbart granulat

syngenta nordics a/s - pymetrozin - vanddispergerbart granulat - 500 g/kg pymetrozin

Armure Emulsionskoncentrat Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

armure emulsionskoncentrat

syngenta nordics a/s - difenoconazol, propiconazol - emulsionskoncentrat - 150 g/l difenoconazol ; 150 g/l propiconazol

Azacitidine Celgene União Europeia - dinamarquês - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Quofenix União Europeia - dinamarquês - EMA (European Medicines Agency)

quofenix

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - ef-erhvervede infektioner - antibakterielle midler til systemisk brug, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Azacitidine Mylan União Europeia - dinamarquês - EMA (European Medicines Agency)

azacitidine mylan

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Phelinun União Europeia - dinamarquês - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.